A new microchip invented by Scripps Research scientists can reveal how a person's antibodies interact with viruses—using just ...

Annexon has completed enrollment in its phase 3 ARCHER II trial of vonaprument (formerly ANX007) for dry age-related macular ...

Mass spectroscopic analysis of material that immunoprecipitated with an anti-C1q antibody found an enrichment of proteins associated with ribosomes and RNA-binding proteins. C1q is highly cationic ...

Annexon announces positive topline results from pivotal phase 3 trial for first-in-class C1q blocking antibody ANX005 in Guillain-Barré syndrome. News release. Annexon, Inc. June 4, 2024.

In multiple regression analysis, a higher number of urinary erythrocytes (OR 3.2292; CI 1.2585-8.2858; p = 0.0148) and anti-C1q antibodies (OR 1.0288; CI 1.0016-1.0568; p = 0.0380) best ...

The right antibody can play a key role in revealing the presence, quantity, dynamics, and even binding interactions of a target protein. However, finding the right antibody from over 2 million ...